Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of romosozumab in postmenopausal osteoporosis with inadequate response to prior therapy
jRCT1051210070Recruiting
- Sponsor
- Osaka University Hospital
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of romosozumab in osteoporosis, sponsored by Osaka University Hospital. Primary endpoints: Change in lumbar spine bone mineral density at 6 and 12 months and Change in femoral bone mineral density at 6 and 12 months. Started Dec 2019; status: recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT1051210070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051210070.